問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Municipal Siaogang Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

黃志富Huang, Jee-Fu
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

Recruiting Trial

48Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃志富

List

131Cases

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

  • Condition/Disease

    advanced stage hepatocellular carcinoma

  • Test Drug

    Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2020-10-01 - 2023-11-21

Phase II

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    MK-3655

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated3Sites

2014-06-01 - 2016-04-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection.

  • Condition/Disease

    Hepatitis C Virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2016-04-30

Phase III

A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

2014-12-01 - 2017-06-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection in the Asia Pacific

  • Condition/Disease

    Chronic HCV GT 1, GT 4 and GT 6 Infection

  • Test Drug

    MK-5172A

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2015-03-01 - 2019-06-30

Phase II/III

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

  • Condition/Disease

    Chronic Hepatitis C

  • Test Drug

    MK-5172A

Participate Sites
10Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital-Taipei

未分科

彭成元
China Medical University Hospital

Digestive System Department

2012-02-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-05-01 - 2023-02-22

Phase I/II

A Phase 1b/2a, Open-Label Study to Evalute the Safety, Tolerability and Immunogenicity of VTP-300 with or wuthout Nivoulumab in Participants with Chronic Hepatitis B infecttion

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    ChAdOx1-HBV; MVA-HBV; Nivolumab

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2020-02-01 - 2021-01-31

Phase I

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)

  • Condition/Disease

    Chronic hepatitis B virus (CHB) infection

  • Test Drug

    EDP 514

Participate Sites
10Sites

Recruiting3Sites

Terminated7Sites

2018-01-01 - 2020-12-31

Phase II

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

  • Condition/Disease

    Chronic HBV Infection (Genotype A or B)

  • Test Drug

    ARB-001467 Injection (2 mg/mL)

Participate Sites
6Sites

Terminated4Sites

彭成元
China Medical University Hospital-Taipei

未分科

林俊彥
Linkou Chang Gung Medical Foundation

Digestive System Department

1 8 9 10 11 12 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB